The ISABELA studies are enrolling now
The ISABELA clinical studies are researching an investigational add-on medication, GLPG1690, for people with idiopathic pulmonary fibrosis (IPF). In this context, an “add-on” medicine is something you take in addition to your standard treatment from your doctor. There are two identical designed studies being conducted in order to verify the results.
The main purpose of these studies is to see how GLPG1690 works together with your current standard treatment on your lung function and IPF disease in general. The study will also investigate how well GLPG1690 is tolerated. If you are interested in participating, visit the Frequently Asked Questions or look for a study center in your area.